文/梧桐兄弟 6 月 6日，上交所公布对 北京天星医疗股份有限公司科创板 IPO终止审核的决定，直接原因是保荐机构 中金公司 独自撤回保荐。公司申报 IPO于2023年 9 月 2 6 日 获得受理， 2023年 10 月 30 日 收到交易所问询 ， 但直到终止审核，未见公布问询回复 。公司本次 IPO拟募资 8.8 亿元。 一、运动医学医疗器械，国产第一，净利润逾 6000万 公司是一家运动医学创新医疗器械企业，主要从事运动医学植入物、有源设备及耗材，以及手术工具的研发、生产与销售。 截至 2024年9月30日，公司已获得20张 III 类医疗器械注册证、17张II类医疗器械注册证，并且已获得15个产品的CE认证，以及产品获得美国、英国、澳大利亚、 印度、印度尼西亚和阿拉伯联合酋长国等国家的医疗器械注册证/备案证书。 报告期各期，公司营业收入分别为 7,301.30万元、14,797.05万元、24,119.48万元、22,293.40万元， | 项目 | 2024. 9. 30/ | 2023. 12. 31/ | 2022.12.31/ | 2021.12.31/ | | --- | --- | -- ...

Group 1 - The stock of Buke Co., Ltd. (688160) has a comprehensive score of 46.80, indicating a weak performance [1] - The main cost analysis shows that the current main cost is 88.30 yuan, with a 5-day main cost of 87.01 yuan, a 20-day main cost of 90.36 yuan, and a 60-day main cost of 96.00 yuan [1] - Over the past year, the stock has not reached its upper limit and has experienced one lower limit [1] Group 2 - As of June 9, 2025, the northbound capital data indicates a holding of 479,000 shares, accounting for 0.57% of the circulating shares, with a net purchase of 87,000 shares yesterday [1] - The short-term pressure level is at 90.60 yuan, while the short-term support level is at 83.23 yuan [2] - The capital flow data for June 9, 2025, shows a net inflow of 1,122,500 yuan from main funds, which is 1% of the total transaction amount [2]

键凯科技688356 时间: 2025年6月9日星期一 60.33分综合得分 5日主力成本 67.91 元 较强 趋势方向 主力成本分析 73.50 元 当日主力成本 75.03 元 20日主力成本 62.15 元 60日主力成本 周期内涨跌停 过去一年内该股 涨停 0次 中期压力位 次 北向资金数据 持股量23.18万股 占流通比0.38% 昨日净买入-2.55万股 昨日增仓比-0.042% 5日增仓比-0.083% 20日增仓比0.071% 跌停 0 技术面分析 79.15 短期压力位 72.11 短期支撑位 79.15 60.10 中期支撑位 目前短线趋势不慎明朗，静待主力资金选择方向； 目前中期趋势不慎明朗，静待主力资金选择方向 K线形态 暂无特殊形态 资金流数据 2025年06月09日的资金流向数据方面 主力资金净流入690.61万元 占总成交额5% 超大单净流入658.08万元 大单净流入32.52万元 散户资金净流出109.29万 关联行业/概念板块 化学制药 3.61%、医疗器械概念 1.68%、创新药 4.24%等 （以上内容为自选股写手差分机完成，仅作为用户看盘参考，不能作为操作依据。） ...

er 医疗器械产业链 上游 中游 下游 电子元件 高值医用耗材 医院 骨科植入、血管介入、神经外科、 眼科、口腔、血液净化、电生理与 为大型医疗设备提供电子元件 公立/民营医院;一级、二 电路板、芯片等电子零部件 级、三级、未定级医院。 原材料 低值医用耗材 基层医疗卫 医用卫生材料及敷科类、注射穿刺 类、医用高分子材料类、医用消毒 类、麻醉耗材类、手术室耗材类医 、 生机构 如橡胶、塑料、电子、钢铁、 紧固件、有色金属等特殊材料 包括乡镇卫生院、诊所、 村卫生室等。 软件系统 医疗设备 专业公共工 功能程序化软件、诊断图象处 理软件、诊断数据处理软件等 医用医疗设备和家用医疗设备 生机构 新兴技术 IVD (体外诊断) 包含疾控中心、妇幼保健 机构等 人工智能、物联网等新兴科技 技术在医疗器械领域应用。 体外诊断仪器和体外诊断试剂两大 部分。 其他 e 医疗器械市场规模 根据QYResearch的研究统计,2024年全球医疗器械规模达到了6358亿美元。预测,2031年全球医疗器械规模将 达到9098亿美元。2025-2031的复合增长率是5.1% 10000000 16.00% ■ 全球医疗器械市场规模（ ...

Core Viewpoint - MaiPu Medical plans to acquire 100% equity of YiJie Medical through a combination of share issuance and cash payment, despite YiJie Medical's continuous losses and the transaction being classified as a related party transaction but not a restructuring listing [2][4][6]. Company Overview - MaiPu Medical primarily engages in the research, production, and sales of high-performance implantable medical devices in the neurosurgery field, including products like artificial dura mater patches and craniofacial repair systems [4]. - YiJie Medical focuses on providing minimally invasive interventional solutions for cerebrovascular diseases, developing and selling products such as neurointerventional catheters and thrombectomy catheters [4][6]. Financial Performance - YiJie Medical has reported continuous losses from 2022 to 2024, with revenues of 0.8364 million, 11.9419 million, and 24.4136 million yuan, and net losses of 31.8646 million, 29.5142 million, and 26.158 million yuan respectively [6]. - In contrast, MaiPu Medical's revenue has shown growth from 195 million to 278 million yuan between 2022 and 2024, with net profits increasing from 35.8918 million to 78.8542 million yuan [6]. Strategic Intent - The acquisition aims to expand MaiPu Medical's product offerings in the neurosurgery and interventional fields, integrating channel resources and enhancing its sales system [4][5]. - The deal is expected to improve MaiPu Medical's industry position in the neurology sector and facilitate easier market entry for YiJie Medical's products [5]. Market Context - The cardiovascular and cerebrovascular intervention market is experiencing significant growth, with the market size for neurovascular interventional medical consumables in China projected to reach 43.2 billion yuan by 2028, reflecting a compound annual growth rate of 36.5% from 2022 [9]. - The increasing prevalence of cerebrovascular diseases due to an aging population is driving demand for innovative interventional treatment solutions [9]. Transaction Details - The acquisition will involve issuing shares at a price of 41.40 yuan per share and raising matching funds at 48.03 yuan per share, although the estimated value of the target assets has not been disclosed [7]. - The transaction is classified as a related party transaction, with connections to MaiPu Medical's controlling shareholder [7].

一次创新思维的碰撞，一场探索医疗科技创新的合作之旅！ 你将获得 医生 ×CEO ×工程师 ×投资人 强强联合，破解医疗器械创新难题！ 培训信息 如果你对 医疗器械创新、医工结合、技术转化 充满兴趣，那么这次 上海交通大学医学院 × 附属医院 × 生物医 学工程学院 联合打造的 「医疗器械医工创新转化工作坊」 ，就是你的绝佳机会！ 让医学痛点与工程技术深度融合，打造医疗创新产品，助力成果转化！ 是否曾有一个医疗创新的想法，却不知如何落地？ 是否苦于医生与工程技术团队难以有效协作？ 是否希望掌握医疗器械从概念到市场的完整路径？ 课程亮点 Biodesign 医工创新方法论： 全球前沿医工创新模式，助力高效转化 顶级医工专家亲授： 上海交大医学院、附属医院、生物医学工程学院权威师资 需求挖掘 × 创意生成： 从临床实际出发，转化医学需求为创新解决方案 跨学科高端人脉圈： 医生、工程师、投资人共创，共享资源 瑞金医院转化医学中心参访： 近距离接触医疗器械创新最前沿 ✅ 精准洞察 | 医疗器械产业趋势，抢占市场先机 ✅ 实战赋能 | 设计思维 × 跨学科合作，掌握创新转化路径 ✅ 高端社群 | 结识医生、科研人员、产业 ...

Core Viewpoint - Beijing Tianxing Medical Co., Ltd. has terminated its IPO on the Shanghai Stock Exchange's Sci-Tech Innovation Board due to the withdrawal of its sponsor, as per the relevant regulations [1] Company Overview - Tianxing Medical is an innovative medical device company specializing in sports medicine, focusing on the research, production, and sales of sports medicine implants, active devices, consumables, and surgical tools [1] - As of September 30, 2024, the company has established a complete matrix of 47 approved sports medicine products, including several first domestically approved products in the implant field [1] Market Position - The company has built a strong brand presence in the sports medicine sector, covering over 3,000 hospitals across 31 provinces, autonomous regions, and municipalities [2] - In 2023, Tianxing Medical held approximately 4% of the Chinese sports medicine medical device market, ranking first among domestic companies [2] Financial Performance - The company reported revenues of approximately CNY 73.01 million, CNY 148 million, CNY 241 million, and CNY 223 million for the years 2021, 2022, 2023, and the first nine months of 2024, respectively [2] - Net profits for the same periods were approximately CNY -110 million, CNY 40.34 million, CNY 63.58 million, and CNY 64.08 million [2] Financial Metrics - As of September 30, 2024, total assets amounted to CNY 550.99 million, with equity attributable to shareholders of CNY 446.13 million [3] - The company's asset-liability ratio was 16.20% as of September 30, 2024, showing a decrease from previous years [3] - The net profit attributable to shareholders was CNY 6.41 million for the first nine months of 2024, with a basic earnings per share of CNY 1.38 [4] Investment Plans - The total amount of funds raised will be used entirely for projects related to the company's main business, including a smart factory project in Suzhou and product research and development [2]

Core Viewpoint - Maipu Medical announced a restructuring plan to acquire 100% of Yijie Medical, which is expected to expand its product offerings in the neurosurgery field, despite concerns over potential financial impacts due to Yijie Medical's current losses [2][3]. Group 1: Company Overview - Maipu Medical is the only company in China's neurosurgery field that offers a comprehensive range of implantable medical devices, including artificial dura mater patches and absorbable hemostatic agents [2]. - Yijie Medical specializes in the research, design, and sales of vascular interventional medical devices for neurology, with products such as neurointerventional catheters and balloon dilation catheters [2]. Group 2: Financial Performance - In 2024, Maipu Medical reported a net profit of 78.85 million yuan, showing a growth trend from 2022 to 2024 [3]. - Yijie Medical is projected to incur net losses of 29.51 million yuan in 2023 and 26.16 million yuan in 2024, raising concerns about the impact of the acquisition on Maipu Medical's financial performance [3]. Group 3: Market and Competitive Landscape - The acquisition is seen as a strategic move to enhance Maipu Medical's product categories by integrating biocomposite material technology into the interventional field [2]. - There are concerns regarding market competition, as existing products in the neurointerventional medical device sector maintain high market shares, and potential new products could disrupt the market [3].

Group 1 - The core viewpoint of the announcement is to encourage internal whistleblowers to report major violations related to the quality and safety of drugs and medical devices, thereby enhancing regulatory oversight and public trust in these products [1][2] - The announcement specifies that internal whistleblowers must provide clear evidence of violations that have not been previously known to regulatory authorities, and that these reports must lead to administrative penalties or criminal prosecutions [1][2] - The policy aims to leverage the detailed and credible information that internal whistleblowers can provide, which is expected to increase the likelihood of identifying significant risks and violations in the pharmaceutical and medical device sectors [1][2] Group 2 - The reward system for whistleblowers includes a maximum reward of 1 million yuan per case, with the specific amount determined by discussions between the drug supervision department and local government finance departments [3] - The implementation of this policy is part of a broader initiative to promote social governance in drug and medical device quality safety, with the aim of preventing and curbing major illegal activities in the sector [2][3] - Following the announcement, some provincial drug supervision departments have begun to adopt similar policies to encourage internal reporting of violations, indicating a trend towards more robust regulatory frameworks in the industry [3]

Company Overview - Qingdao Yihai Overseas Surgical Instrument Co., Ltd. has been established with a registered capital of 2 million RMB, fully owned by Qingdao Lujian Health Technology Co., Ltd. [1] - The legal representative of the company is Zhao Lin [1]. Shareholding Structure - Qingdao Lujian Health Technology Co., Ltd. holds 100% of the shares in Qingdao Yihai Overseas Surgical Instrument Co., Ltd. [2]. Business Scope - The business scope includes the operation of Class III medical devices, food sales, and various other services such as technology import and export, health consulting, and special medical food sales [2]. - The company is registered under the scientific research and technical service industry, specifically in technology promotion and application services [2].